What is the Purpose of this Study?
This study will evaluate the safety and side effects of an investigational drug called BMS-986449 in patients with an advanced solid tumor that has grown or come back. The study also aims to determine the dose of BMS-986449 that can be given to patients for treatment of certain types of cancer. BMS-986449 will be given alone, or in combination with another drug called nivolumab. Researchers will examine how the body absorbs and processes BMS-986449, as well as how the participant’s cancer responds to treatment with BMS-986449 alone or in combination with nivolumab. Nivolumab is an immunotherapeutic antibody that is approved for the treatment of certain types of cancer, but its use in combination with BMS-986449 is investigational.
Eligibility
- * All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy (measurable by Response Evaluation Criteria in Solid Tumors \[RECIST\] v1.1), and have received, be refractory to, ineligible for, or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant.
- * Part 1A may have a solid malignancy of any histology.
- * Part 1B is restricted to participants with Non-small cell lung cancer (NSCLC).
Where can I participate?
Cedars-Sinai Cancer at The Angeles Clinic and Research Institute
More about this Clinical Trial
What is the full name of this clinical trial?
CA1201001: Phase 1/2 Study of BMS-986449 Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors